The U.S. Centers for Medicare & Medicaid Services will publish the first 10 Medicare Part D drugs selected for the new Medicare Drug Price Negotiation Program by Sept. 1, CMS announced yesterday.
The negotiated maximum fair prices for these drugs will be announced by Sept. 1, 2024, and prices will be in effect starting Jan. 1, 2026, CMS said in a Jan. 11 news release. The agency said in the future it will select for negotiation 15 more Part D drugs for 2027, 15 more Part B or Part D drugs for 2028, and 20 more Part B or Part D drugs for each year after that, as outlined in the Inflation Reduction Act. It did not give dates for these subsequent rounds.
Under the IRA, manufacturers will have to provide the maximum fair price to 340B covered entities for these drugs only if the maximum fair price is lower than the 340B ceiling price. CMS has not yet said how it will implement this provision.